Antivenom Cross-Reactivity Revealed Across Five Deadly Iranian Viper Venoms

Snakebite envenomation remains one of the world’s most neglected public health crises, with the World Health Organization estimating that roughly 5.4 million people are bitten each year, producing between 1.8 and 2.7 million cases of envenoming and up to 137,000 deaths. Antivenom, produced by hyperimmunising large mammals such as horses or sheep with snake venom, is the only specific treatment for systemic envenoming, yet its effectiveness is constrained by enormous geographic and biological variability in venom composition. A new study from the Razi Vaccine and Serum Research Institute in Iran has now mapped, in unusual detail, how well experimental antivenoms recognise and neutralise the venoms of five medically important Iranian vipers, offering a data-driven blueprint for designing better regional therapies.

The research, published in Veterinary Medicine and Science, focused on five viperid species responsible for a large share of clinically significant snakebites in Iran: Montivipera raddei, Macrovipera lebetina, Echis carinatus, Pseudocerastes persicus, and Gloydius caucasicus. Because victims rarely identify the species that bit them, clinicians typically rely on polyvalent antivenoms raised against panels of local snakes. Whether such broad-spectrum products actually work, however, depends on how much antigenic overlap exists between the venoms of different species, a question the Iranian team set out to answer with a combination of biochemical profiling, immunological assays, and gold-standard in vivo neutralisation tests.

The first step was to quantify how lethal each venom is. In a murine model, the researchers determined median lethal dose values by intravenous injection and probit regression, and the spread was striking. Gloydius caucasicus proved the most toxic, with an LD50 of 0.22 micrograms per gram of body weight, followed closely by Macrovipera lebetina at 0.27, Montivipera raddei at 0.30, and Echis carinatus at 0.56. Pseudocerastes persicus was considerably less potent at 0.87 micrograms per gram. These figures align with earlier reports that Gloydius venom is among the most dangerous in Iran, while also underscoring how toxicity can shift with geography, snake age, diet, and even the route of administration used in testing.

To understand the molecular basis of these differences, the team separated venom proteins by SDS-PAGE electrophoresis under both reducing and non-reducing conditions. All five venoms shared prominent bands at roughly 22, 50, and 130 to 150 kilodaltons, although band intensities varied by species. The approximately 22-kilodalton band, which intensified and shifted to around 14 to 15 kilodaltons after disulphide bonds were broken, is consistent with secreted phospholipase A2 enzymes, small cysteine-rich toxins that drive multiple pharmacological effects in viper envenoming. The 50-kilodalton band, strongest in Pseudocerastes persicus, likely corresponds to snake venom metalloproteinases, the haemorrhage-causing enzymes classified into P-I, P-II, and P-III subclasses. The high-molecular-weight 130 to 150 kilodalton band, which fragmented upon reduction, plausibly represents L-amino acid oxidase homodimers, whose subunits typically run at 55 to 70 kilodaltons.

Reverse-phase high-performance liquid chromatography added a second layer of resolution, generating species-specific chromatographic fingerprints. Gloydius caucasicus showed a dominant mid-range cluster of peaks accounting for nearly 65 percent of detected area, with a single component representing over 30 percent. Echis carinatus displayed the broadest complexity, with seven significant peaks and a mid-range cluster covering 65.6 percent of the area, consistent with proteotranscriptomic studies showing that Echis venoms are richly diverse mixtures of metalloproteinases, serine proteases, C-type lectin-like proteins, and phospholipases A2. Montivipera raddei produced a comparatively simple profile dominated by one late-eluting component, while Macrovipera lebetina resolved into eight main peaks. Pseudocerastes persicus stood apart with a distinctive early-eluting fraction absent from all other venoms, a feature attributed to abundant phospholipases A2, L-amino acid oxidases, and unique peptide components reported in prior proteomic work.

With the venoms characterised, the researchers immunised New Zealand White rabbits, dividing them into monovalent groups receiving single venoms and a polyvalent group receiving an equal-volume mixture of all five. Indirect ELISA then measured how each antivenom bound homologous and heterologous venoms. The results revealed a remarkable spectrum of cross-reactivity. Antivenom raised against Montivipera raddei was the broadest recognizer, binding Pseudocerastes persicus at 92 percent, Echis carinatus at 91 percent, Macrovipera lebetina at 95 percent, and Gloydius caucasicus at 80 percent of homologous levels. Pseudocerastes persicus antivenom also cross-reacted strongly with most relatives, but only weakly with Gloydius caucasicus at 44 percent. At the other extreme, Gloydius caucasicus antivenom showed the lowest heterologous binding of all, while the polyvalent preparation bound every venom at 95 percent or higher, confirming that combining five immunogens did not compromise the antibody response.

Crucially, binding did not always predict neutralisation, a well-known limitation of ELISA, which cannot distinguish neutralising antibodies from those that merely recognise epitopes. In vivo assays challenging mice with five lethal doses of venom pre-incubated with antivenom told a more nuanced story. Each monovalent antivenom was most potent against its own venom, as expected, but meaningful cross-neutralisation emerged in several pairings. Macrovipera lebetina and Montivipera raddei antivenoms neutralised Pseudocerastes persicus venom at 1.17 and 1.07 milligrams of venom per millilitre of antivenom respectively, while Pseudocerastes antivenom neutralised Montivipera raddei at 0.49 and Echis carinatus at 0.66 milligrams per millilitre. Gloydius caucasicus antivenom, in sharp contrast, neutralised only its homologous venom and showed little or no activity against any heterologous venom tested. The polyvalent formulation neutralised all five venoms, performing best against Pseudocerastes persicus and Echis carinatus and weakest against Gloydius caucasicus.

The authors interpret these patterns through the lens of shared and divergent toxin families. Broad cross-reactivity among Montivipera, Macrovipera, and Pseudocerastes likely reflects conserved metalloproteinases and phospholipases A2, the dominant immunogens of Old World viper venoms. The poor performance of Gloydius caucasicus antivenom mirrors findings from other Gloydius species, whose distinct venom compositions, possibly including unique haemorrhagic metalloproteinases, demand species-specific antibodies. Comparable studies elsewhere reinforce the picture: Thai monovalent antivenoms show variable cross-neutralisation across Asian vipers, Pakistani Viper Antivenom cross-neutralises saw-scaled and Russell’s viper subspecies across the Indian subcontinent, and the polyvalent Inoserp Europe covers several Vipera, Montivipera, and Macrovipera species, consistent with conserved toxin architecture within the subfamily Viperinae.

The practical implications are direct. Venoms that generate both strong cross-reactivity and cross-neutralisation, such as those of Montivipera raddei and Macrovipera lebetina, are strong candidates for inclusion in immunisation mixtures aimed at paraspecific protection. Venoms with narrow cross-neutralisation, above all Gloydius caucasicus, must be explicitly represented in any formulation intended to cover the full Iranian viper spectrum. The findings also echo clinical experience: a study of 44 viper-envenomed patients treated with Iranian polyvalent antivenom documented reduced envenoming severity and normalised coagulation parameters within 12 hours, supporting the therapeutic value of polyspecific products when species identification is uncertain.

The researchers caution that their SDS-PAGE and RP-HPLC data are comparative fingerprints rather than definitive proteomic assignments, and that converting chromatographic peaks into precise toxin identities requires LC-MS/MS-based venomics and antivenomics. They also note that immunological profiles depend heavily on the host animal used for antibody production, so results from rabbits cannot be extrapolated directly to horse-derived commercial antivenoms. Even so, by integrating lethality, protein profiling, binding, and neutralisation into a single comparative framework, the study delivers exactly the kind of evidence base needed to rationally reformulate antivenoms for a region where five vipers, each with its own toxic signature, share the same landscapes and the same emergency rooms.

Subject of Research: Immunological cross-reactivity and neutralizing efficacy of antivenom against five medically important Iranian viper venoms

Article Title: Immunological Cross‐Reactivity and Neutralizing Efficacy of Antivenom Against Five Medically Important Iranian Viper Venoms

Article References: Khamehchian, S., Tahoori, F., Rabie, H., Nasrabadi, N. N., & Tebianian, M. (2026). Immunological Cross‐Reactivity and Neutralizing Efficacy of Antivenom Against Five Medically Important Iranian Viper Venoms. Veterinary Medicine and Science, 12(5), Article e71193. https://doi.org/10.1002/vms3.71193

Image Credits: AI Generated

DOI: 10.1002/vms3.71193

Keywords: snakebite, antivenom, Iranian vipers, venom cross-reactivity, neutralization, venomics, ELISA, LD50, phospholipase A2, metalloproteinases, polyvalent antivenom, Gloydius caucasicus